-
EP4003986
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4003986
| EP4003986 - INHIBITOR COMPOUNDS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 29.04.2022 Database last updated on 03.09.2024 | |
| Former | The international publication has been made Status updated on 29.01.2021 | Most recent event Tooltip | 12.06.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Cincera Therapeutics Pty Ltd Level 9 31 Queens St Melbourne, VIC 3000 / AU | [2022/22] | Inventor(s) | 01 /
FLYNN, Bernard Luke 45 Heads Rd Donvale, Victoria 3052 / AU | 02 /
LE, Giang 40 Eric Avenue Templestowe Lower, Victoria 3107 / AU | 03 /
YANG, Shuxin Unit 507/37-43 Breese Street Brunswick, Victoria 3056 / AU | [2022/22] | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [2022/22] | Application number, filing date | 20843975.2 | 24.07.2020 | [2022/22] | WO2020AU50763 | Priority number, date | AU20190902614 | 24.07.2019 Original published format: AU 2019902614 | [2022/22] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021012018 | Date: | 28.01.2021 | Language: | EN | [2021/04] | Type: | A1 Application with search report | No.: | EP4003986 | Date: | 01.06.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 28.01.2021 takes the place of the publication of the European patent application. | [2022/22] | Search report(s) | International search report - published on: | AU | 28.01.2021 | (Supplementary) European search report - dispatched on: | EP | 01.02.2023 | Classification | IPC: | C07D413/12, C07D417/12, C07D401/12, C07D413/14, C07D401/14, A61P11/00, A61P13/12, A61P1/16, A61P9/10, A61P17/02, A61K31/4439, A61K31/497, A61K31/501, A61K31/506, C07D403/12 | [2023/09] | CPC: |
C07D403/12 (EP,IL,KR);
C07D413/12 (EP,AU,IL,KR,US);
A61K31/4439 (KR);
A61K31/506 (KR);
A61P1/16 (EP,AU,IL,KR);
A61P11/00 (EP,AU,IL,KR,US);
A61P13/12 (EP,AU,IL);
A61P17/02 (EP,AU,IL);
A61P43/00 (KR);
A61P9/10 (EP,AU,IL);
C07D401/12 (EP,AU,IL,KR,US);
C07D401/14 (EP,AU,IL,KR,US);
|
| Former IPC [2022/22] | C07D413/12, C07D417/12, C07D401/12, C07D413/14, C07D401/14, A61P11/00, A61P13/12, A61P1/16, A61P9/10, A61P17/02, A61K31/4439, A61K31/497, A61K31/501, A61K31/506 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/22] | Title | German: | HEMMERVERBINDUNGEN | [2022/22] | English: | INHIBITOR COMPOUNDS | [2022/22] | French: | COMPOSÉS INHIBITEURS | [2022/22] | Entry into regional phase | 21.01.2022 | National basic fee paid | 21.01.2022 | Search fee paid | 21.01.2022 | Designation fee(s) paid | 21.01.2022 | Examination fee paid | Examination procedure | 21.01.2022 | Examination requested [2022/22] | 24.08.2023 | Amendment by applicant (claims and/or description) | 24.08.2023 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 15.06.2022 | Renewal fee patent year 03 | 13.09.2023 | Renewal fee patent year 04 | 12.06.2024 | Renewal fee patent year 05 | Penalty fee | Additional fee for renewal fee | 31.07.2023 | 04 M06 Fee paid on 13.09.2023 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2018112077 (CENTAURUS THERAPEUTICS [US]); | International search | [A]WO2008142073 (NOVARTIS AG [CH], et al); | [A]WO2012164103 (UNIV ZUERICH [CH], et al); | [A]WO2015155738 (RUDD CHRISTOPHER [US]); | by applicant | US2923661 | US5684018 | WO0023419 |